Home/SiSaf/Dr. Suzanne Saffie-Siebert
DS

Dr. Suzanne Saffie-Siebert

Founder and CEO

SiSaf

SiSaf Pipeline

DrugIndicationPhase
miRNA-based therapyPancreatic Ductal Adenocarcinoma (Solid Tumors)Pre-clinical
siRNA-based therapyMetastatic CancerPre-clinical
SiS-ADO2 (siRNA)Autosomal Dominant Osteopetrosis Type II (ADO2)Pre-clinical